Table 1 CHOL vaccines in clinical trials
From: mRNA vaccine development for cholangiocarcinoma: a precise pipeline
Vaccine | Form | Combination | Indication | n | Clinical trial | Status |
|---|---|---|---|---|---|---|
Prevnar | Pneumococcal 13-valent conjugate vaccine | Therapeutic autologous dendritic cells, external beam radiation therapy | Unresectable HCC and unresectable ICC | 26 | NCT03942328 | Recruiting |
Recombinant fowlpox-CEA (6D)/TRICOM vaccine | Fowlpox | Sargramostim | Advanced stage tumors including CHOL | 48 | NCT00028496 | Completed |
Wilms’ tumor 1 antigen | DC vaccine | Gemcitabine | Advanced stage tumors including CHOL | 11 | UMIN000004063 [25] | Completed |
Autologous tumor lysate | DC vaccine | – | Resectable intrahepatic cholangiocarcinoma | 62 | UMIN000005820 [26] | Completed |
CEA RNA-pulsed DC tumor vaccine | DC vaccine | – | Advanced stage tumors including extrahepatic bile duct cancer | 24 | NCT00004604 | Completed |
Amph modified KRAS peptides | Peptide | Amph-CpG-7909 | Advanced stage tumors including CHOL | 18 | NCT04853017 | Recruiting |